A great deal of GLP-1 coverage blurs the line between drugs you can actually be prescribed and drugs that are still in trials. That distinction is not academic — it determines whether a substance has been evaluated for safety at all, and it is the gap that grey-market sellers operate in. Here is where each one actually stands.
| Medication | Status | Form | Can you get it? |
|---|---|---|---|
| Foundayo (orforglipron) | FDA approved April 1, 2026 | Daily oral tablet | Yes |
| Wegovy HD (semaglutide 7.2 mg) | FDA approved | Weekly injection | Yes |
| CagriSema | Filed with FDA December 2025; under review | Weekly injection | No |
| Retatrutide | Phase 3 trials (TRIUMPH) | Weekly injection | No |
Approved: Foundayo (orforglipron)
The headline development of 2026. Orforglipron, sold by Eli Lilly as Foundayo, was first approved on April 1, 2026 for use with a reduced-calorie diet and increased physical activity to reduce excess body weight in adults with obesity, or adults with overweight who also have weight-related medical problems.
What makes it different is not the mechanism but the format. It is a non-peptide small molecule, which means it survives digestion well enough to work as an ordinary tablet. Lilly describes it as the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions — a real departure from older oral GLP-1 products with strict empty-stomach dosing routines.
On efficacy, it is the weakest of the three modern options. Lilly reports average weight loss of 11.1% at the top 17.2 mg dose over 72 weeks in adults without diabetes, against roughly 14.9% for semaglutide in STEP 1 and 20.9% for tirzepatide in SURMOUNT-1. That is the trade: a simpler daily habit, a smaller average effect.
We cover dosing, the full trial tables, the CYP3A4 interaction that can cap your dose, and cost in our orforglipron guide.
Approved: Wegovy HD (semaglutide 7.2 mg)
The FDA approved a higher 7.2 mg dose of injectable semaglutide, marketed as Wegovy HD, for chronic weight management in adults with obesity or overweight with weight-related conditions. The approval was based on data from the phase 3b STEP UP trial.
This is a dose escalation rather than a new molecule — the same semaglutide, higher. Reporting on the approval indicates it follows time at the standard 2.4 mg dose, with one source describing at least four weeks at 2.4 mg first. In practice it is an option for people already established on semaglutide whose response has plateaued, not a starting point, and whether it suits you is a clinical judgement.
It is already priced and available: NovoCare Pharmacy lists the Wegovy HD pen from $399/month, and GoodRx Care publishes $399 for one carton, $798 for two, and $1,197 for three cartons per month, with that offer stated to end December 31, 2026.
Not approved: CagriSema
CagriSema is Novo Nordisk's combination of semaglutide with cagrilintide, an amylin analogue. Novo submitted it to the FDA in December 2025, based on the REDEFINE 1 and REDEFINE 2 pivotal trials, and the agency was expected to review the application during 2026.
It remains investigational and is not approved in the US or the EU. Trial reporting described average weight loss around 23% on one treatment-effect analysis, which would place it at the top of the class if it reaches market — but a filing is not an approval, and reported trial figures are not the same as a label.
Not approved: retatrutide
Retatrutide is Eli Lilly's triple agonist, acting at GLP-1, GIP, and glucagon receptors. It remains in phase 3 trials, including the TRIUMPH program, and is not approved for any indication. It cannot be lawfully prescribed as a medicine, and reporting in 2026 suggested Lilly might submit it for regulatory review by the end of that year.
It attracts more search interest than almost any approved drug in this class, largely on the strength of early trial numbers. That interest has created a market that deserves a direct warning.
“Research use only” peptides are not medicines
Because retatrutide is unapproved, no legitimate pharmacy can dispense it. Substances sold online under that name — commonly labelled “research use only” or “not for human consumption” — sit entirely outside the drug regulatory system. Nobody has verified what is in the vial, at what concentration, or whether it is sterile.
The labelling is not a technicality; it is how sellers avoid drug regulation while relying on buyers to inject the contents anyway. FDA has separately stated it is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. carrying false information on the product label. If a seller is willing to misrepresent an approved molecule, an unapproved one carries every one of those risks and no accountability at all.
What this means practically
Three things follow from the current picture.
The oral era has genuinely started. With Foundayo approved and the Wegovy pill already on the market, needle avoidance is no longer a reason to go without treatment. Both cost less than the injectables at their introductory doses — LillyDirect lists Foundayo from $149 and NovoCare lists the Wegovy pill from $149 — though both rise substantially at higher doses.
More options are coming, and that is not a reason to wait. If CagriSema clears review it would add a meaningfully more effective option, and retatrutide may follow. But approval timelines slip, trials fail, and a newly approved drug arrives at launch pricing with no coverage. Treating a condition you have now with medicines that exist now is usually the better decision, and it is your doctor's to help you make.
Check what your provider actually offers. Foundayo is already listed by LifeMD, Found, Ivím Health, Alloy, and GoodRx Care. Several larger platforms have not added it yet, and formularies in this market change faster than the marketing pages describing them.
How to read pipeline coverage
A few habits make this class of news much easier to parse:
- “Filed” and “submitted” are not “approved.” CagriSema has been filed since December 2025 and still cannot be prescribed.
- Trial percentages are not label claims. Reported figures depend on which analysis is used, and headline numbers usually reflect the most favourable one.
- Cross-trial comparisons are indicative only. Different populations, durations, and protocols. Useful for direction, not for ranking.
- If you can buy it online without a prescription, it is not the approved drug. This is the single most reliable test.
Frequently Asked Questions
What new GLP-1 medications were approved in 2026?+
Two significant additions. Foundayo (orforglipron) was first approved on April 1, 2026 — the first oral GLP-1 receptor agonist for chronic weight management that can be taken any time of day without food or water restrictions. The FDA also approved Wegovy HD, a higher 7.2 mg dose of injectable semaglutide, for chronic weight management, based on data from the phase 3b STEP UP trial.
Is retatrutide FDA approved?+
No. Retatrutide is an investigational Eli Lilly medication that remains in phase 3 trials, including the TRIUMPH program. It is not approved for any indication and is not available by prescription. Reporting in 2026 indicated Lilly might submit it for regulatory review by the end of the year, but submission is not approval.
Is CagriSema approved?+
No. Novo Nordisk submitted CagriSema to the FDA in December 2025, based on the REDEFINE 1 and REDEFINE 2 pivotal trials, and the agency was expected to review the application during 2026. It remains investigational and is not approved in the US or EU.
Why does approval status matter so much?+
Because unapproved substances sold as "retatrutide" or other pipeline compounds are not medicines. They have not been evaluated for safety, purity, or potency, they are frequently marketed as "research use only" to sidestep drug regulation, and nobody is accountable for what is in the vial. FDA has separately stated it is aware of fraudulent compounded semaglutide and tirzepatide carrying false information on the label.
How does the new oral pill compare to the injections?+
Lilly reports average weight loss of 11.1% at the top 17.2 mg orforglipron dose over 72 weeks. For comparison, semaglutide produced about 14.9% at 68 weeks in STEP 1 and tirzepatide about 20.9% at the top dose in SURMOUNT-1. These are separate trials rather than head-to-head comparisons, but the direction is consistent: the pill trades some efficacy for the convenience of a daily tablet.
Who is Wegovy HD for?+
It is a higher 7.2 mg dose of the same semaglutide molecule, approved for chronic weight management in adults with obesity, or overweight with weight-related conditions. Reporting on the approval indicates it follows time at the 2.4 mg dose — one source describes at least four weeks at 2.4 mg first. It is an escalation option for people already on semaglutide rather than a starting point, and your prescriber decides whether it fits.
Should I wait for retatrutide instead of starting treatment now?+
That is a conversation for your doctor, but as a general matter, waiting for an unapproved drug means waiting an unknown amount of time for an unknown outcome. Trials can fail, timelines slip, and approval does not guarantee affordability or coverage. Decisions about treating a condition you have now are usually better made with the medicines that exist now.
Sources
- Foundayo (Lilly) — approval status, indication, 72-week trial results, dosing and warnings
- Eli Lilly and FDA announcements of Foundayo (orforglipron) approval; Drugs.com FDA approval history recording first approval April 1, 2026
- FDA announcement of the higher 7.2 mg dose of Wegovy (Wegovy HD) for chronic weight management, based on the phase 3b STEP UP trial
- Novo Nordisk / PR Newswire — CagriSema FDA filing December 2025 based on REDEFINE 1 and REDEFINE 2; Drugs.com approval status recording “FDA Approved: No”
- Reporting on retatrutide phase 3 status (TRIUMPH program) and possible regulatory submission timing
- FDA — statements regarding fraudulent compounded semaglutide and tirzepatide carrying false label information
- Comparator trial figures: STEP 1 (semaglutide) and SURMOUNT-1 (tirzepatide). Verified August 5, 2026.
🇺🇸Medical Disclaimer
Your health, your doctor. This article describes regulatory status and published trial reporting. It is not medical advice, and we are researchers rather than clinicians. Never inject a substance that has not been dispensed as a medicine by a licensed pharmacy. Approval status and pipeline timelines change; figures here were verified August 5, 2026 and should be re-checked before relying on them.